{"id":"varicella-zoster-virus","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site reactions (erythema, swelling, pain)"},{"rate":"3-5","effect":"Varicella-like rash (vaccine strain)"},{"rate":"10-15","effect":"Fever"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":{"setId":"0280849d-5c78-4a9d-8941-4eab429f6bd8","title":"SHINGRIX (ZOSTER VACCINE RECOMBINANT, ADJUVANTED) KIT SHINGRIX (ZOSTER VACCINE RECOMBINANT, ADJUVANTED) INJECTION, SOLUTION [GLAXOSMITHKLINE BIOLOGICALS SA]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains a weakened form of the varicella zoster virus that replicates in host cells sufficiently to trigger both cellular and humoral immune responses, generating protective antibodies and T-cell memory against the virus. This immunological priming prevents primary VZV infection (chickenpox) and reduces the risk and severity of reactivation disease (herpes zoster/shingles) later in life.","oneSentence":"Varicella zoster virus (VZV) is a live attenuated viral vaccine that stimulates immune response to prevent chickenpox and herpes zoster infections.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:56.888Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of varicella (chickenpox) in susceptible individuals"},{"name":"Prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults"}]},"trialDetails":[{"nctId":"NCT05703607","phase":"PHASE1, PHASE2","title":"A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-01-25","conditions":"Shingles, Herpes Zoster Infection, Human","enrollment":485},{"nctId":"NCT07481604","phase":"PHASE2","title":"Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"CHA Vaccine Institute Co., Ltd.","startDate":"2026-04","conditions":"Herpes Zoster","enrollment":135},{"nctId":"NCT05923970","phase":"","title":"Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2024-11-09","conditions":"Vaccination Failure, Vaccine Response Impaired","enrollment":200},{"nctId":"NCT07473427","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-05-01","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT07475000","phase":"PHASE3","title":"Second Dose of Varicella Vaccine in Healthy Children","status":"RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-01-28","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT07293065","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2025-12-15","conditions":"Herpes Zoster","enrollment":12000},{"nctId":"NCT05580458","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-13","conditions":"Herpes Zoster","enrollment":225},{"nctId":"NCT07321808","phase":"","title":"Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2023-05-16","conditions":"Immunocompromised Patients","enrollment":300},{"nctId":"NCT07415252","phase":"PHASE3","title":"SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years","status":"NOT_YET_RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-06-05","conditions":"Varicella (Chickenpox)","enrollment":780},{"nctId":"NCT07406360","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-04-13","conditions":"Measles","enrollment":1209},{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT05622682","phase":"","title":"Vaccine Immune Recovery After Leukemia","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2022-09-28","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":89},{"nctId":"NCT01953900","phase":"PHASE1","title":"iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2014-04","conditions":"Osteosarcoma, Neuroblastoma","enrollment":26},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT07311148","phase":"PHASE2","title":"A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-10-23","conditions":"Herpes Zoster (HZ), Shingles, VZV","enrollment":840},{"nctId":"NCT06901362","phase":"","title":"Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2025-04-01","conditions":"Healthy, Healthy Adult","enrollment":401},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT06890416","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-04","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":526},{"nctId":"NCT07205796","phase":"PHASE2","title":"A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Shenxin Biotechnology Co., Ltd","startDate":"2026-05-01","conditions":"Herpes Zoster","enrollment":480},{"nctId":"NCT05304351","phase":"PHASE2","title":"Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Curevo Inc","startDate":"2022-02-02","conditions":"Herpes Zoster, Shingles","enrollment":1516},{"nctId":"NCT03604406","phase":"PHASE2","title":"The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kevin Winthrop","startDate":"2014-05-08","conditions":"Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT05041426","phase":"PHASE2","title":"Letermovir for CMV Prevention After Lung Transplantation","status":"COMPLETED","sponsor":"Fernanda P Silveira, MD, MS","startDate":"2021-12-06","conditions":"Lung Transplant, CMV","enrollment":16},{"nctId":"NCT07047053","phase":"","title":"Evaluation of the Anti-VZV Vaccine Response of Patients With Immune-mediated Systemic Inflammatory Diseases Vaccinated in the Care Setting","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-06-10","conditions":"Vaccination Varicella-zoster Virus, Immune-mediated Systemic Inflammatory Diseases","enrollment":50},{"nctId":"NCT06070961","phase":"","title":"Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2024-05-07","conditions":"Follicular Lymphoma","enrollment":56},{"nctId":"NCT05630846","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-12-14","conditions":"Measles; Mumps; Rubella; Chickenpox, Measles","enrollment":801},{"nctId":"NCT06409494","phase":"PHASE1","title":"Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"EuBiologics Co.,Ltd","startDate":"2024-07-15","conditions":"Varicella Zoster Virus Infection, Herpes Zoster","enrollment":72},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT06994052","phase":"PHASE4","title":"Study on Booster Immunization With Varicella Vaccine at Different Intervals","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"VZV, Varicella Immunisation","enrollment":412},{"nctId":"NCT06987942","phase":"PHASE4","title":"Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"Varicella, Influenza Vaccine","enrollment":899},{"nctId":"NCT05550194","phase":"PHASE4","title":"VZV in the Enteric Nervous System: Pathogenesis and Consequences","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-03-27","conditions":"Achalasia","enrollment":40},{"nctId":"NCT06961721","phase":"PHASE4","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2025-05","conditions":"Prevention of Herpes Zoster","enrollment":600},{"nctId":"NCT05604911","phase":"","title":"Herpes Virus Infections in Kidney Transplant Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Susanne Dam Nielsen, MD, DMSc","startDate":"2023-01-01","conditions":"Kidney Transplant; Complications, Varicella Zoster Virus Infection, Vaccine-Preventable Diseases","enrollment":280},{"nctId":"NCT06874842","phase":"PHASE1","title":"Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older","status":"RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-03-13","conditions":"Herpes Zoster (HZ)","enrollment":92},{"nctId":"NCT05966090","phase":"PHASE3","title":"A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-07-28","conditions":"Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections","enrollment":530},{"nctId":"NCT06891872","phase":"PHASE4","title":"Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2025-05","conditions":"Varicella (chickenpox), MMR Vaccine, DTaP Vaccine","enrollment":720},{"nctId":"NCT06335849","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2024-03-27","conditions":"Herpes Zoster","enrollment":48},{"nctId":"NCT03134196","phase":"PHASE4","title":"Zoster Eye Disease Study","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-08-23","conditions":"Herpes Zoster Ophthalmicus","enrollment":527},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT06851832","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older","status":"RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-02-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":960},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT05789615","phase":"","title":"Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-04-01","conditions":"CMV Infection, Hematopoietic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT05095701","phase":"PHASE4","title":"An Immunity Persistence Study of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-12-18","conditions":"Varicella","enrollment":703},{"nctId":"NCT06314724","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-02-29","conditions":"Varicella","enrollment":642},{"nctId":"NCT06482216","phase":"","title":"Correlation of Protection Against Varicella in an Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2025-10-10","conditions":"Varicella","enrollment":400},{"nctId":"NCT06484686","phase":"PHASE4","title":"An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-16","conditions":"Varicella","enrollment":414},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT06375512","phase":"PHASE1","title":"A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shenzhen Shenxin Biotechnology Co., Ltd","startDate":"2024-07-05","conditions":"Herpes Zoster","enrollment":150},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT05991427","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-11-07","conditions":"Herpes Zoster","enrollment":65},{"nctId":"NCT06654700","phase":"PHASE3","title":"Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).","status":"NOT_YET_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2024-12-09","conditions":"Herpes Zoster","enrollment":1200},{"nctId":"NCT05636436","phase":"PHASE1","title":"Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2022-12-07","conditions":"Herpes Zoster","enrollment":132},{"nctId":"NCT05856084","phase":"PHASE2","title":"Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2023-05-07","conditions":"Herpes Zoster","enrollment":924},{"nctId":"NCT06447779","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2024-07-13","conditions":"Herpes Zoster","enrollment":25000},{"nctId":"NCT04169009","phase":"PHASE4","title":"Persistence of Protection by Shingrix","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-07-28","conditions":"Herpes Zoster","enrollment":105},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT06614816","phase":"PHASE3","title":"Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-02-10","conditions":"Chickenpox Vaccines","enrollment":1200},{"nctId":"NCT06592456","phase":"PHASE3","title":"A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-07-21","conditions":"Chickenpox Vaccines","enrollment":1200},{"nctId":"NCT06068608","phase":"PHASE1","title":"A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy","status":"UNKNOWN","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2023-09-12","conditions":"Varicella","enrollment":48},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT06407388","phase":"","title":"Ultrasound Findings in Diabetic Pregnancies","status":"RECRUITING","sponsor":"Eastern Virginia Medical School","startDate":"2023-06-01","conditions":"Diabetes","enrollment":156},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT06313762","phase":"NA","title":"Use of Virtual Reality in the Reduction of Pain After the Administration of Vaccines Among Children in Primary Care Centers.","status":"COMPLETED","sponsor":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","startDate":"2022-01-18","conditions":"Pain, Pediatrics, Vaccination","enrollment":300},{"nctId":"NCT05015686","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-09-30","conditions":"Varicella","enrollment":2400},{"nctId":"NCT05924685","phase":"PHASE4","title":"PREPARE-iVAC Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2023-08-22","conditions":"COVID-19 Vaccines, Varicella Zoster Vaccine, Vaccine Response","enrollment":110},{"nctId":"NCT05422508","phase":"PHASE2","title":"Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination","status":"RECRUITING","sponsor":"Green Cross Corporation","startDate":"2022-07-05","conditions":"Varicella","enrollment":230},{"nctId":"NCT05158777","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2022-02-13","conditions":"Varicella","enrollment":2480},{"nctId":"NCT04072497","phase":"PHASE1, PHASE2","title":"A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-20","conditions":"Herpes Zoster","enrollment":522},{"nctId":"NCT01911065","phase":"PHASE4","title":"T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Herpes Zoster","enrollment":54},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT04523246","phase":"EARLY_PHASE1","title":"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2020-09-01","conditions":"Herpes Zoster, Allergy and Immunology, Corona Virus Infection","enrollment":217},{"nctId":"NCT05047770","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-07","conditions":"Herpes Zoster","enrollment":2013},{"nctId":"NCT06088745","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine","status":"RECRUITING","sponsor":"Beijing Luzhu Biotechnology Co., Ltd.","startDate":"2023-09-28","conditions":"Vaccine-Preventable Diseases, Herpes Zoster","enrollment":4},{"nctId":"NCT03702231","phase":"PHASE2","title":"Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-12-07","conditions":"Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL)","enrollment":116},{"nctId":"NCT05952505","phase":"PHASE4","title":"Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines","status":"UNKNOWN","sponsor":"Shanghai Municipal Center for Disease Control and Prevention","startDate":"2023-08","conditions":"SARS-CoV-2 Infection, Varicella, Measles","enrollment":540},{"nctId":"NCT04384016","phase":"PHASE4","title":"Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2021-04-17","conditions":"Chickenpox","enrollment":201},{"nctId":"NCT05839301","phase":"PHASE3","title":"A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2023-04-27","conditions":"Varicella","enrollment":1200},{"nctId":"NCT05669625","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2022-12-26","conditions":"Varicella","enrollment":12440},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT05130398","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2021-04-09","conditions":"Ebola Virus Disease","enrollment":120},{"nctId":"NCT01693380","phase":"PHASE4","title":"Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2009-05","conditions":"Influenza, Acute Respiratory Infection","enrollment":1742},{"nctId":"NCT05750017","phase":"PHASE1","title":"A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine","status":"UNKNOWN","sponsor":"Beijing Luzhu Biotechnology Co., Ltd.","startDate":"2023-03-23","conditions":"Herpes Zoster, Vaccine-Preventable Diseases","enrollment":66},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT05460429","phase":"PHASE4","title":"Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-30","conditions":"Varicella","enrollment":37920},{"nctId":"NCT05470855","phase":"PHASE4","title":"Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-06","conditions":"Varicella","enrollment":45400},{"nctId":"NCT05664152","phase":"NA","title":"An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years","status":"UNKNOWN","sponsor":"GC Biopharma Corp","startDate":"2023-02","conditions":"Varicella Zoster Virus Infection","enrollment":250},{"nctId":"NCT05245838","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2022-01-10","conditions":"Shingles, Herpes Zoster, Vaccine-Preventable Diseases","enrollment":150},{"nctId":"NCT04516408","phase":"NA","title":"Recombinant Zoster Vaccine in Stable SLE Patients","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2021-04-20","conditions":"Herpes Zoster, Recombinant Zoster Vaccine, Systemic Lupus Erythematosus","enrollment":464},{"nctId":"NCT05526820","phase":"PHASE4","title":"A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-04-08","conditions":"Varicella","enrollment":450},{"nctId":"NCT01600079","phase":"","title":"ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-15","conditions":"Herpes Zoster, Shingles","enrollment":1505647},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT01190228","phase":"PHASE3","title":"Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08-25","conditions":"Japanese Encephalitis, Varicella","enrollment":454},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT05150392","phase":"PHASE3","title":"An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2018-07-11","conditions":"Varicella","enrollment":1193},{"nctId":"NCT04334577","phase":"PHASE3","title":"Study on Efficacy of Attenuated Zoster Vaccine, Live","status":"COMPLETED","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2020-04-20","conditions":"Herpes Zoster","enrollment":25000}],"_emaApprovals":[],"_faersSignals":[{"count":94,"reaction":"OFF LABEL USE"},{"count":77,"reaction":"DRUG INEFFECTIVE"},{"count":74,"reaction":"FATIGUE"},{"count":60,"reaction":"ARTHRALGIA"},{"count":52,"reaction":"COUGH"},{"count":50,"reaction":"CONDITION AGGRAVATED"},{"count":48,"reaction":"PAIN IN EXTREMITY"},{"count":46,"reaction":"BLOOD PRESSURE INCREASED"},{"count":45,"reaction":"PYREXIA"},{"count":44,"reaction":"DIARRHOEA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Varivax"],"phase":"marketed","status":"active","brandName":"varicella zoster virus","genericName":"varicella zoster virus","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Varicella zoster virus (VZV) is a live attenuated viral vaccine that stimulates immune response to prevent chickenpox and herpes zoster infections. Used for Prevention of varicella (chickenpox) in susceptible individuals, Prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}